Influence of Small Molecule Property on Antibody Response

Kai Wen[†], Yuchen Bai[†], Yujie Wei, Chenglong Li, Suxia Zhang, Jianzhong Shen & Zhanhui Wang^{*}

Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Veterinary Medicine, China Agricultural University, Beijing Key Laboratory of Detection Technology for Animal–Derived Food Safety, and Beijing Laboratory of Food Quality and Safety Beijing 100193, China

Antibodies with high titer and affinity to small molecule are critical in the field for the development of vaccines against drugs of abuse, antidotes to toxins and immunoassays for compounds. However, little is known regarding how properties of small molecule *per se* influence and which chemical descriptor could indicate the degree of the antibody response. Based on our previous study, we designed and synthesized two groups of small molecules, called haptens, with varied hydrophobicities to investigate the relationship between properties of small molecules and antibody response in term of titer and affinity. We found that the magnitude of the antibody response is positively correlated with the degree of molecular hydrophobicity and related chemical descriptors. This study provides insight into the immunological characteristics of small molecules themselves and useful clues to produce high–quality antibodies against small molecules.

Small molecule, property, antibody response, hydrophobicity, molecular descriptor, molecular polarity index

Since the last century, antibodies have been highly successful biomedicine, biochemistry in and bioanalysis [1]. Antibodies are glycoproteins derived from the humoral immune naturally responding to macromolecules such as bacteria, viruses and proteins. In the case of low-molecular-weight compounds (<1000 Da), such as pharmaceuticals, poisons and drugs of abuse, these small molecules cannot be effectively recognized by the immune system to induce a subsequent antibody response [2]. To produce antibodies against small molecules, structural analogs of targets, named haptens, should be conjugated to larger molecules, called carriers. As well-established biological reagents, thousands of antibodies against hapten molecules with varied titers and affinities have been produced Unlike antibodies [3]. to macromolecules, desired antibodies to haptens should possess not only high titer but also high affinity for the free molecule, which is essential for their use as biopharmaceutics, antidotes and immunoprobes. Some factors, including hapten design, coupling chemistry, hapten-carrier ratio, carrier type and adjuvant formulation, have been reported to influence antibody response and then antibody formation, as they affect

presentation of the hapten molecule and thus the quality of the immune response [4]. Nowadays, little is known regarding what primarily guarantees a high–quality antibody response to a hapten. In the author's opinion and experience, the decisive factor for antibody response should be the hapten itself; however, how hapten properties themselves influence and which molecular descriptors can indicate or even predict the degree of the antibody response is poorly understood.

To address this question, it is critical to deepen our understanding of the immunogenicity of small molecules, of course, after conjugating to carriers, which will be useful to produce the desired antibody with excellent titer and affinity. Systematic investigation of the relationship between properties of molecules and antibody response small is experimentally challenging due to the large number of variables and the limited number of typical molecular models. Recently, we successfully produced the antibodies against trimethoprim by preferentially exposing the hydrophilic dimethamine of trimethoprim, resulting in a surprisingly high titer and affinity (Figure 1 and Table S1) [5]. Compared with the antibodies obtained bv exposing the hvdrophobic trimethoxyphenyl of trimethoprim in the other reports, the affinity (expressed as IC₅₀ values) of our antibodies are improved by 10-90-fold with higher titers [6].

[†]These authors contributed equally to this work.

^{*}Corresponding authors (email: wangzhanhui@cau.edu.cn)

These results reveal that the hydrophilic groups of haptens seem to account more for a strong antibody response than the hydrophobic groups of haptens. However, recent studies on the immunogenicity and haptenic character of poly (ethylene glycol) (PEG) and other nanoparticles showed that hydrophilic materials usually bear a lower immunogenicity than their hydrophobic counterparts [7]. These opposite results motived us to examine whether the capacity of small molecule to induce antibody response is related with its hydrophobic degree. If not, which of its molecular descriptors could suitably indicates the immunogenicity of small molecule? Since the small molecule itself has the most critical impact on antibody response in the author's opinion.




Figure 1. Chemical structures of haptens. Hapten1a mimics the trimethoxyphenyl of trimethoprim and is synthesized by us. Hapten1b mimics the diaminopyrimidine of trimethoprim and is a commercial compound. Hapten2 group were intentionally designed and synthesized with significantly different hydrophobicities. The molecular descriptors of haptens which excluding the spacer arm were calculated. Dipole moment, μ ; molecular polarity index, MPI.

To understand the immunogenic attributes of small molecules, a simple and logical experiment based on simplified models is necessary. According to the immunizing results of trimethoxyphenyl, we firstly divided trimethoprim into two parts and separately verified the capacity of two resultant haptens to induce an antibody response. As shown in Figure 1, the proposed Hapten1a (in red) mimics the hydrophilic dimethamine moiety of TMP and Hapten1b (in blue) resembles the hydrophobic trimethoxyphenyl moiety of TMB. Secondly, we intentionally designed Hapten2 group with simple structure, which comprised three novel compounds with similar molecular weights and obviously different hydrophobicities (Figure 1). Based on the structural characteristics of three compounds, the order of hydrophobicity is expected to be: Hapten2c > Hapten2b > Hapten2a.The key point in the design of these haptens was the use of the same spacer arm, thus providing structural uniformity to remove the usual "bridge effects" arising from the linker between the hapten and carrier protein [8]. In addition, the similar molecular weight of members of the Hapten2 group ensured a fair comparison, since molecular weight is thought to be an important factor in immunogenicity of small molecule [9].

To ensure the rationality and practicability of these firstly designed, we evaluate haptens their hydrophobicity by using calculation chemistry with the M06-2X density functional and TZVP basis set before synthesis [10]. After obtaining the minimum conformations of the haptens excluding the spacer arm (Figure S4), the maps of electrostatic potential (ESP) mapped van der Waals surface of all haptens are constructed since ESP are closely related to the hydrophobicity of small molecules and could be as an indicator [11]. In addition, we calculated area distribution of different ESP intervals on the van der Waals surface. As shown in Figure 2A, the neutral regions in white of Hapten1a account for a large proportion of van der Waals surface due to the trimethoxyphenyl. In Hapten2, the hapten2c present predominantly neutral with some negative regions at the position of phenyl, is different from hapten2a and hapten2b which have obviously positive ESP in red at amino group and carboxyl group respectively (Figure 2B). More detail, the ESP surface area of Hapten1a is equably distributed between -30 kcal/mol and 30 kcal/mol while that of Hapten1b is concentrated in a narrower range of 0-20 kcal/mol which illustrates a more even surface distribution, roughly implying that significantly Hapten1a possessing lower hydrophobicity than Hapten1b. Similarly, in the group of Hapten2, by comparing the uniformity of ESP distribution, Hapten2c provides the highest molecular hydrophobicity followed by Hapten2b and then Hapten2a (Figure 2B). The calculated hydrophobicity





Figure 2. Electrostatic potential (ESP) mapped *van der Waals* surface (i.e. $\rho = 0.001$ a.u. isosurface) and area distribution of ESP intervals of (A) Hapten1 and (B) Hapten 2. The negative ESP regions are indicated in blue, the positive regions in red and the neutral regions in white.

of haptens support the practicability of these haptens we designed to study the influence of molecular hydrophobicity on antibody response. After confirmation by computational chemistry, the hapten1a and three haptens in Hapten2 group were totally synthesized in four or five steps (Scheme 1, 2, 3) since the hapten1b is commercially available. The detailed synthesis and characterization of haptens were provided in Supporting information (Figure S1).


To conjugate the haptens on a carrier protein, carboxylic acids of all hapten molecules were activated with N-hydroxysulfosuccinimide and dicyclohexylcarbodiimide and then treated with bovine serum albumin (BSA) as immunogens and ovalbumin (OVA) as coating antigens. Since the hapten-carrier ratio could influence the antibody response in animals and the subsequent antibody test [4b, 12], it was controlled carefully in the reasonable range of 13.4 to 17.0 for hapten-BSA and 4.4 to 5.3 for hapten-OVA, respectively (Figure S2-S3 and Table S2). Each hapten-BSA conjugate was used to immunize a set of 10 BALB/c mice with a total of three times at 25-day intervals. The use of 10 mice per hapten minimized the risk of obtaining results overly biased by any individual mouse (Table S4). Antisera are composed of the entire distribution of IgG antibodies present in mouse and provide a comprehensive view of general trends associated with the overall antibody response.

Thus, antisera titer and affinity were assessed by both noncompetitive ELISA and competitive ELISA against the corresponding homologous coating antigen, respectively (described in Supporting information). In the experiment, antibody titer is defined as the dilution of antisera that furnished an OD_{max} between 1.5 and 2.0, while antibody affinity is expressed as the inhibition ratio calculated according to an equation (Supporting information).


Scheme 1. Synthesis of Hapten1a



Scheme 2. Synthesis of Hapten2b and Hapten2a



Scheme 3. Synthesis of Hapten2c



In short, a higher antibody dilution or inhibition ratio indicates a higher antibody response. As shown in Figure 3A, both Hapten1a and Hapten1b induced a significant antibody response. A general trend of gradually increasing titer as immunization continued was seen. Importantly, the antibody titers from Hapten1b were obviously higher than those from Hapten1a. During the immunization period, the antibody titers of Hapten1b were always 10-fold higher than those of Hapten1a, implying a stronger immune response achieved by more hydrophobic Hapten1b (Figure 3A). The performance of antibodies against small molecules should be judged by not only titer but also affinity. The latter is practically more important in the fields of bioanalysis, biochemistry and biomedicine in most cases. Unexpectedly, the antibodies induced by Hapten1a showed a rather poor affinity with an inhibition ratio of only 1%, unlike the antibodies induced by Hapten1b, which showed a greater than 75% inhibition ratio after the third immunization (Figure 3B). Furthermore, no improvement in the inhibition ratio of

antisera for Hapten1a was observed, while the inhibition ratio of Hapten1b slowly increased with subsequent immunizations. These results reveal an obvious relationship between hydrophobicity of small molecule and antibody response, i.e., a higher degree of hydrophobicity of small molecule induced a stronger antibody response, which is opposite to our initial hypothesis supported by our previous study of trimethoprim [5].

To examine the unexpected relationship, three well-designed Hapten2 with varied hydrophobicity are then evaluated as shown in Figure 3C and 3D. The titers and affinities of all Hapten2 analogs increased sharply as immunizations continued, and an improvement in titer of at least 3-fold was achieved at the end of Similarly, a clear immunization. and definite relationship between hydrophobicity of small molecule and antibody titer was again observed with no exception. Moreover, both the highest antibody titer and the highest affinity of the antisera were obtained from the most hydrophobic hapten, Hapten2c. The titer and inhibition ratio of Hapten2c after the third immunization was approximately 7- and 10-fold, 2and 3-fold higher those of Hapten2b and Hapten2a, respectively, demonstrating that the degree of small molecule hydrophobicity was positively correlated with the magnitude of the antibody response, at least in the case of the haptens we prepared. There is little difference in affinity between Hapten2a and Hapten2b, which may be related to similar ESP distribution on molecular surface of the two haptens (Figure 2B). These findings demonstrate the similarity between small molecules and polymers, nanomaterials and proteins, whose hydrophobicity significantly influences their antibody response [7]. Notably, the titers and affinities of all five evaluated haptens in this study were not high, and the IC₅₀ values for the haptens determined by ELISA were all at the μ g/mL level (data not shown), which can be ascribed to the very low molecular weight and simple structures of these haptens.

To identify the appropriate molecular descriptors to indicate the ability of small molecule inducing antibody response, we extracted physicochemical descriptors of haptens such as LogP, molecular




Figure 3. Evaluation of antibody titer and affinity. Antibody titers tested by homologous ELISA using serum from mice (n=10/group) at the 1st, 2nd and 3rd immunization. The titer is defined to be the dilution of antisera when furnishing ODmax between 1.5 and 2.0. Inhibition ratios representing antibody affinities measured by homologous ELISA for their corresponding hapten using serum from mice (n=10/group) at the 1st, 2nd and 3rd immunization. The inhibition ratio is calculated according to an equation described in supporting information. The higher inhibition ratio represents the higher antibody affinity. *P < 0.05 determined by one–way ANOVA. (A) Antibody titer of Hapten1 (B) Inhibition ratio of Hapten1 (C) Antibody titer of Hapten2 (D) Inhibition ratio of Hapten2.

volume/surface, etc. (described in *Supporting information* and shown in Table S3) [10]. As shown in Table S3 and S5, only descriptors related to hydrophobicity, such as dipole moment, LogP, polar surface area and molecular polarity index (MPI), were observed to be directly proportional to the antibody response. MPI is defined for quantitatively measuring polarity of molecules based on ESP on their van der Waals surface, representing the uniformity of ESP distribution. Comparing to dipole moment, LogP, polar surface area, in the author's opinion, MPI maybe a better indicator of a hapten ability to induce an antibody response since it can be obtained easily and appropriately represents the molecular hydrophobicity in most cases [13].

On the contrary, for example, the dipole moment cannot reflect the molecular hydrophobicities of symmetrical molecules, such as triacetone triperoxide and chlorhexidine. The correlation between MPI and antibody affinity was calculated by Person Correlation Matrix and the coefficient is -0.838 which is significant at the 0.05 level (2-tailed). The results clearly demonstrate that the MPI is a meaningful molecular descriptor to indicate the ability of small molecule inducing antibody response, at least in our study.

Despite this, a positive relationship between hapten hydrophobicity and antibody titer was not found between groups, for example, Hapten1a vs Hapten2a (Table S5). In addition, there have been many reports of exceptional

small molecules with high hydrophobicity that produce a low antibody response, which here mainly refers to antibody affinity, such as squalene in comparison to its hydrophilic counterpart, etioporphyrin [14]. Furthermore, molecules with small extremely high some hydrophobicity did not induce an antibody response, such as diisononylcyclohexane-1,2-dicarboxylate and di-2ethylhexyl terephthalate [15]. These results imply that an increase in hydro phobicity of small molecule does not always guarantee and improve antibody response, which is also influenced by other molecular properties of small molecules, such as size, shape, and flexibility, complicating the structure-magnitude correlation. Further study should be conducted by using more typical molecule models with strict control to obtain more precise relationship between molecular properties and antibody response.

In summary, we designed two groups of haptens with different hydrophobicities and systematically investigated the relationship between properties of small molecules and antibody response. A highly positive correlation between molecular hydrophobicity and antibody response was observed. The MPI was suggested to be used as an indicator of ability of small molecule inducing antibody response. These findings provide a deeper understanding of the antibody response of small molecule *per se* and have far–reaching implications for rational hapten design, a critical step toward the development of a new generation of vaccines against drugs of abuse, antidotes to chemical toxins and diagnostic antibodies for small molecules.

Acknowledgements This work was supported by the National Science Foundation of China (Grant No. 31873025).

Conflict of interest The authors declare that they have no conflict of interest.

Supporting information The supporting information is available online at...

 (a) Rchards DA, Maruani A, Chudasama V. *Chem Sci*, 2017, 8: 63–77; (b) Bremer PT, Kimishima A, Schlosburg JE, Zhou B, Collins KC, Janda KD. *Angew Chem Int Ed Engl*, 2015, 55: 3772–5; c) De la Rosa G, Olvera F, Archundia IG, Lomonte B, Alagon A, Corzo G. *Nat Commun*, 2019, 10: 3642; (d) Wenthur CJ, Zhou B, Janda KD. Nature, 2017, 548: 476-479.

- 2 (a) Dengl S, Sustmann C, Brinkmann U. Immunol Rev, 2016, 270: 165–77; (b) Quinones–Reyes G, Agullo C, Mercader JV, Abad–Somovilla A. Angew. Chem Int Ed Engl, 2019, 58: 9134–9139.
- 3 Singh M K, Srivastava S, Raghava GPS, Varshney GC. Bioinformatics, 2006, 22: 253–255.
- 4 (a) Skolnick P. *Trends Pharmacol Sci*, 2015, *36*, 628–635; (b) Jalah R, Torres OB, Mayorov AV, Li F, Antoline JF, Jacobson AE, Rice KC, Deschamps JR, Beck Z, Alving CR, Matyas GR. *Bioconjugate Chem*, 2015, *26*: 1041–53; (c) Cai X, Tsuchikama K, Janda KD. *J Am Chem Soc*, 2013, *135*: 2971–2974.
- 5 Li H, Ma S, Zhang X, Li C, Dong B, Mujtaba MG, Wei Y, Liang X, Yu X, Wen K, Yu W, Shen J, Wang Z. J Agric Food Chem, 2018, 66: 11170–11179.
- (a) Han X, Sheng F, Kong D, Wang Y, Pan Y, Chen M, Tao Y, Liu Z, Ahmed S, Yuan Z, Peng D. *Food Chem*, 2019, 280: 20–26; (b) Chen Y, Liu L, Xie Z, Zhu J, Song S, Kuang H. *Food Agric Immunol*, 2017, 28: 1046–1057; (c) Chen Y, Liu L, Song S, Kuang H, Xu C. *Food Agric Immunol*, 2016, 27: 830–840; (d) Martlbauer E, Meier R, Usleber E, Terplan G. *Food Agric Immunol*, 1992, 4: 219–228.
- (a) Moyano DF, Goldsmith M, Solfiell DJ, Landesman–Milo D, Miranda O R, Peer D, Rotello VM. J Am Chem Soc, 2012, 134: 3965–3967; (b) Seong SY, Matzinger P. Nat Rev Immunol, 2004, 4: 469–478; c) Li B, Yuan Z, Hung H C, Ma J, Jain P, Tsao C, Xie J, Zhang P, Lin X, Wu K, Jiang S. Angew Chem Int Ed Engl, 2018, 57: 13873–13876; (d) Li B, Xie J, Yuan Z, Jain P, Lin X, Wu K, Jiang S, Angew Chem Int Ed. Engl, 2018, 57: 4527–4531; (e) Moyano DF, Liu Y, Ayaz F, Hou S, Puangploy P, Duncan B, Osborne BA, Rotello VM, Chem, 2016, 1: 320–327.
- 8 Pryde DC, Jones LH, Gervais DP, Stead DR, Blakemore DC, Selby MD, Brown AD, Coe JW, Badland M, Beal DM, Glen R, Wharton Y, Miller GJ, White P, Zhang N, Benoit M, Robertson K, Merson JR, Davis HL, McCluskie MJ. *PLoS One*, 2013, 8: e76557.
- 9 Wallace MB, Iverson BL. J Am Chem Soc, 1996, 118: 251– 252.
- (a) Weigend F, Ahlrichs R. *Phys Chem Chem Phys*, 2005, 7: 3297–3305; (b) Zhao Y, Truhlar DG. *Theor Chem Acc*, 2008, 120: 215–241.
- 11 (a) Du Q, Arteca GA. J Comput Aid Mol Des, 1996, 10: 133– 144; (b) Du Q, Liu P, Mezey PG. J Chem Inf Model, 2005, 45:

347-353.

- Fodey TL, Greer NM, Crooks SR. *Anal Chim Acta*, 2009, 637: 328–32.
- 13 Lu T. Multiwfn Manual, version 3.6(dev), Section 3.21.1, available at http://sobereva.com/multiwfn (accessed Aug 30, 2018).
- 14 Al Qaraghuli MM, Palliyil S, Broadbent G, Cullen DC, Charlton KA, Porter AJ. *BMC Biotechnol*, 2015, 15: 99.
- 15 Baldofski S, Canitz CJ, Garbe LA, Schneider RJ. Anal Biochem, 2018, 543: 90-96.

SUPPORTING INFORMATION

Influence of Small Molecule Property on Antibody Response

Kai Wen[†], Yuchen Bai[†], Yujie Wei, Chenglong Li, Suxia Zhang, Jianzhong Shen &

Zhanhui Wang*

Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Veterinary

Medicine, China Agricultural University, Beijing Key Laboratory of Detection Technology for

Animal-Derived Food Safety, and Beijing Laboratory of Food Quality and

Safety Beijing 100195, China.

	Contents	Pages			
1	Materials and apparatus	S5			
2	Buffers	S5			
3	Apparatus	S5			
4	Synthesis and characterization of haptens				
5	Preparation and characterization of protein conjugates	S18-S25			
6	The molecular descriptors of haptens obtained by computational chemistry	S25			
7	Immunization procedure of mice				
8	The determination of antibody titers and affinity	S28-S30			
9	References	S 31			

Table of Contents for Supporting Information

Supplementary Schemes, Tables and Figures

	Legends	Pages
Table S1	Previous reported haptens of trimethoprim and related conjugation chemistry, IC_{50} values and titers.	S4
Scheme 1	The synthetic route of Hapten1a	S 6
Scheme 2	The synthetic route of Hapten2a and Hapten2b	S 9
Scheme 3	The synthetic route of Hapten2c	S 11
Figure S1	The mass spectra and ¹ H NMR spectra of (A) Hapten1a, (B) Hapten2a, (C) Hapten2b, (D) Hapten2c.	S14-S17
Figure S2	MALDI–TOF-MS of (A) BSA, (B) Hapten1a-BSA (C) Hapten1b -BSA (D) Hapten2a-BSA, (E) Hapten2b-BSA, (F) Hapten2c-BSA.	S19-S21
Figure S3	MALDI–TOF-MS of (A) BSA, (B) Hapten 1a-OVA (C) Hapten1b -OVA (D) Hapten2a-OVA, (E) Hapten2b-OVA, (F) Hapten2c-OVA.	S22-S24
Table S2	The selected conjugates with similar hapten-to-protein molar ratios	S25
Figure S4	The minimum energy conformations of haptens	S26
Table S3	Molecular descriptors of all haptens	S27
Table S4	The information of immunization procedures	S28
Table S5	The detailed information of antibodies titers and inhibition ratios from three immunizations	S 30

Hapten structures	Conjugation chemistry	Antibody types	IC ₅₀ (ng/mL)	Titers a	References
The following has	aptens reported in literatures which all expose diami	inopyrimidine to immun	e system		
		Polyclonal antibody	>6.0 ^b	1,500	1
$^{\rm NH_2}$		from rabbit	>6.0 ^b	_ ^c	2
	Glutaraldehyde used as conjugation reagents	Monoclonal	4.14	32,000	3
H_2N N OCH_3 OCH_3		antibody from mouse	1.98	-	4
The following three	haptens we prepared which much expose diaminop	yrimidine moiety to imr	nune system		
NH_2	COOH Dicyclohexylcarbodiimide and N-hydroxysuccinimide used as conjugation reagents		0.232	16,000	5
			0.067	60,000	
$H_2N'N' \qquad \bigcirc O' \sim COOH OCH_3$			0.2	20,000	
NH ₂ NOCH ₃	Dicyclohexylcarbodiimide and	Monoclonal antibody from	0.15	40,000	
H ₂ N N COOH	<i>N</i> -hydroxysuccinimide used as conjugation reagents	mouse	0.24	40,000	6
NH ₂ N H ₂ N N N OCH ₃ OCH ₃ COOH	Dicyclohexylcarbodiimide and N-hydroxysuccinimide used as conjugation reagents		0.17	60,000	

Table S1. Previous reported haptens of trimethoprim and related conjugation chemistry, IC₅₀ values and titers of antibodies.

^a The titer here was defined that the concentration of antibody generated the OD values ranged 1.5 to 2.0.

^b The papers have not reported IC₅₀ values and only provided detection limits. Usually the IC₅₀ value was about 10 times of detection limit in an immunoassay.

^c Not exhibited in the work.

1. Materials and apparatus

Bovine serum albumin (BSA), horseradish peroxidase (HRP), *N*-hydroxysuccinimide (NHS), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The substrate 3,3',5,5'-tetramethylbenzidine (TMB) system was obtained from the Beijing WDWK Biotechnology Co., Ltd. (Beijing, China). All other chemicals and solvents were of analytical grade or better and were obtained from the Beijing Chemical Reagent Co. (Beijing, China). Reverse osmosis water, pyrogen free (RO water) was prepared using a Milli-Q water purification system (Millipore, Bedford, MA, USA).

2. Buffers


The common buffer solutions used in the experiment are listed: (1) coating buffer (0.05 mol/L) carbonate buffer, pH 9.6); (2) phosphate buffer solution (PBS buffer, 0.01 mol/L, pH 7.4); (2) blocking buffer (2% skim milk powder (w/v)); (3) washing buffer (PBST, 10 mmol L⁻¹ PBS buffer with 0.05% Tween-20 (v/v)), pH 7.2); (4) antibody diluent buffer (10 mmol/L washing buffer with 0.2% albumin, (w/v)); (5) Goat anti-mouse IgG (HRP labeled) dilution buffer (PBS buffer (PBS buffer containing 5% albumin (w/v)); (7) stopping reagent (2 mol/L H₂SO₄).

3. Apparatus

Polystyrene microplates were obtained from Corning Inc (Costar 2592, Corning, NY, USA). Optical density (OD) was recorded on SpectraMax M5 (Downingtown, PA, USA). The chemical structures of all haptens were confirmed by liquid chromatography triple quadrupole mass spectrometry (Thermo, USA) and nuclear magnetic resonance spectrometry (NMR) DRX (Bruker, Rheinstetten, Germany). The conjugation ratio was determined by matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI–TOF-MS) (Bruker, Rheinstetten, Germany).

4. Synthesis and characterization of haptens


4.1 Synthesis of Hapten1a



Scheme 1. The synthetic route of Hapten1a.


Hapten1a was prepared based on the following scheme in 5 steps.

Step 1 Synthesis of compound 3 (2,4-diaminopyrimidine-5-carbonitrile)




Guanidine hydrochloride (19.11 g, 200 mmol) was suspended in anhydrous ethanol (600 mL), 2-(ethoxymethylene)malononitrile (27.20 g, 200 mmol) was added in one portion. The mixture was stirred at ambient for 10 min. Sodium ethoxide (6.80 g, 100 mmol) was added in 2 portions in 10 min. The reaction mixture was heated at 81 °C (oil bath) for 2 h and then incubated at ambient temperature (25 °C) for 16 h. Solvent was removed in vacuum to give a yellow residue. Sat. ammonium chloride (500 mL) and pure water (100 mL) were added to the residue. The resulting mixture was stirred for 10 min, filtered, and then the desired product (24.01 g, 177.85 mmol, 89%). ¹H NMR (300 MHz, DMSO- d_6) δ 6.93 (s, br, 2H) 7.10 (s, br, 2H), 8.17 (s, 1H) was obtained by drying the yellow solid in vacuum.

Step 2 Synthesis of compound 4 (2,4-diaminopyrimidine-5-carbaldehyde)



Compound 3 (24.01 g, 177.80 mmol) was added to a slurry of Raney nickel (50% in water, 20.00 g) followed by addition of formic acid (88% in water, 200 mL). The resulting mixture was then heated under reflux (125 °C, oil bath) for 7 h. Then stirred at ambient temperature for 16 h. The reaction mixture was filtered, the cake was washed with formic acid (100 mL). The filtrate was combined and concentrated to afford a yellow residue. The residue was poured onto ammonia (28%, 200 mL). The resulting mixture was stirred for 30 min. The yellow solid was collected by filtration, dried in hot air to gain a yellow solid (21.09 g, 86%) as desired product (¹H NMR (300 MHz, DMSO- d_6) δ 7.13 (s, 2H) 7.54 (s, br, 1H), 7.82 (s, br, 1H), 8.32 (s, 1H), 9.46 (s, 1H)).

Step 3 Synthesis of compound 6 ((E)-ethyl 3-(2,4-diaminopyrimidin-5-yl)acrylate)



A suspension of compound **4** (5.52 g, 40 mmol), compound **5** (16.70 g, 48 mmol) in DMF (100 mL) was heated at 120 °C for 4 h. The mixture was cooled to room temperature. Water (400 mL) was added to the residue then stirred for 30 min. Yellow precipitate appeared. The mixture was extracted with ethyl acetate (400 mL \times 4). The combined organic layers were washed with water (600 mL), brine (600 mL), dried Na₂SO₄. Solvent removal under vacuum gave a yellow powder (19.02 g). The powder was washed with a mixture of petroleum ether and ethyl acetate (1:1, 200 mL \times 3) and concentrated to give a powder as desired product (3.20 g, 38%).


Step 4 Synthesis of compound 7 (ethyl 3-(2,4-diaminopyrimidin-5-yl)propanoate)



A mixture of compound **6** (3.20 g, 15.30 mmol), palladium on carbon (10%, 1.00 g) in ethanol (150 mL) was hydrogenated at 50 $^{\circ}$ C under a hydrogen balloon for 48 h. The mixture was


cooled to room temperature. Palladium on carbon was removed by filtration. The filtrate was concentrated to afford a residue (3.10 g). The mixture was refluxed in a mixture of MeOH and CHCl₃ (1:3, 100 mL) and filtered. The solid was discarded. The filtrate was concentrated to give a residue, which was washed with a mixture of petroleum ether and dichloromethane (10:1, 40 mL \times 2) to give a residue as desired crude product (2.10 g, 62%). The material was used in next step without further purification.

Step 5 Synthesis of Hapten1a



To a suspension of compound 7 (2.10 g, crude, 10 mmol) in MeOH (15 mL) was added a solution of NaOH (2.40 g, 60 mmol) in water (15 mL). The resulting mixture was stirred at room temperature for 2 h. TLC monitoring indicated that compound 7 was consumed completely. The mixture was neutralized with HCl (3 M, 20 mL) to adjust pH value to 3-4. The mixture was extracted with dichloromethane (20 mL \times 3). The aqueous layer was concentrated to give a residue. The residue was refluxed in a mixture of MeOH and water (5:1, 60 mL) and filtered while hot. The filtrate was concentrated to give a residue. The residue was refluxed in a filtered while hot. The filtrate was concentrated to give an off-white solid as pure target compound (1.50 g, 82%) (1H NMR (300 MHz, D₂O) δ 2.65-2.67 (m, 4H), 7.50 (s, 1H). ESI-MS found 181 (M-H)).

4.2 Synthesis of Hapten2a and Haten2b



Scheme 2. The synthetic route of Hapten2a and Hapten2b.

Target Hapten2a and Hapten 2b was prepared based on the following scheme.

Step 1 Synthesis of compound 2 (methyl 2-bromoisonicotinate)

СООН		COOCH3
\land	MeOH, H ₂ SO ₄	
N Br	Step 1, 80%	
1		2


Concentrated sulphate acid (2 mL) dropwise was added to a mixture of compound **1** (20.20 g, 100 mmol) in MeOH (200 mL). The mixture was heated under reflux for 5 h. The mixture was cooled to room temperature. Ethyl acetate (300 mL) was then added. The mixture was washed with sat. NaHCO₃ to neutral. The mixture was then dried over sodium sulphate. The solvent was removed under vacuum to give a light-yellow oil as desired compound 2 (17.20 g, 80%). *Step 2* Synthesis of compound 4 ((E)-methyl 2-(3-tert-butoxy-3-oxoprop-1-enyl)isonicotinate)

$$\begin{array}{c} \text{COOCH}_3 \\ \\ N \\ \text{Br} \end{array}^+ \\ \begin{array}{c} 0 \\ 0 \\ \text{Step 2, 32\%} \end{array} \xrightarrow{\text{COOCH}_3} \\ \begin{array}{c} \text{COOCH}_3 \\ \\ N \\ 0 \\ \text{COOCH}_3 \\ \\ N \\ 0 \\ \text{COOCH}_3 \\ \\ N \\ 0 \\ \text{COOCH}_3 \\ \\ 0 \\ \\ 0 \\ 0 \\ \\ 0 \\ 0 \\ \end{array}$$

Under nitrogen atmosphere, to a mixture of compound **2** (2.16 g, 10 mmol), potassium carbonate (1.65 g, 12 mmol), triethylenediamine (112.30 mg, 1 mmol), Bu₄NBr (3.87 g, 12 mmol) was added DMF (20 mL) via syringe. Then Pd(OAc)₂ (112.3 mg, 0.50 mmol) and compound **3** (3.20 g, 25 mmol) were added. The mixture was heated at 120 °C under nitrogen atmosphere for 6 h. The mixture was cooled to room temperature. Water (100 mL) was then added. The mixture was extracted with dichloromethane (50 mL \times 3). The combined organic layers were dried over Na₂SO₄. The mixture was then concentrated. The residue obtained was subject to silica gel column

separation (petroleum ether : ethyl acetate=30 :1) to give a light-yellow solid (880 mg, 32 %) as desired compound **4**.

Step 3 Synthesis of compound 5 (methyl 2-(3-tert-butoxy-3-oxopropyl)isonicotinate)



To a solution of compound 4 (5.00 g, 19 mmol) in ethyl acetate (60 mL) was added palladium on carbon (10%, 2.00 g). The mixture was hydrogenated under hydrogen gas balloon for 16 h. The mixture was then filtered to remove the palladium on carbon. The filtrate was concentrated to give a light-yellow oil as desired compound 5 (4.73 g, 94%).

Step 4 Synthesis of Hapten2b




TFA (10 mL) was added to a solution of compound **5** (4.73 g, 17.80 mmol) in dichloromethane (30 mL). The mixture was then refluxed for 4 hours. The mixture was cooled to room temperature. Solvent was removed under vacuum. To the mixture was added water (50 mL) and the pH value was adjusted to 4 with the addition of 1 N HCl. The precipitate was filtered and collected and dried under vacuum to give desired Hapten2b as a white solid (2.53 g, 68%). ¹H NMR (400 M Hz, DMSO-d6) δ 2.70 (t, J = 7.2 Hz, 2H), 3.07 (t, J = 7.2 Hz, 2H), 3.90 (s, 3H), 7.65-7.74 (m, 2H), 8.69 (d, J = 4.8 Hz, 1H), 12.13 (s, 1H).

Step 5 Synthesis of Hapten2a



To a mixture of Hapten2b (3.78 g, 18 mmol) in MeOH (40 mL) cooled to 0 °C was added a solution of methyl amine (4.41 g, 30%, 90 mmol). The mixture was then heated at 50 °C for 8 h. The mixture was cooled to room temperature and concentrated. Water (50 mL) was added. The pH value of the mixture was adjusted to 4 with the addition of 1 N HCl. The precipitate was collected via filtration to give a solid. Further drying under vacuum gave a white solid as desired product **3** (1.72 g, 46%). ¹H NMR (500 MHz, DMSO- d_6) δ 2.71 (t, *J* = 7.0 Hz, 2H), 2.80 (d, *J* = 4.5 Hz, 3H), 3.04 (t, *J* = 7.0 Hz, 2H), 7.56 (dd, *J* = 1.5 Hz, 5.5 Hz, 1H), 7.64 (s, 1H), 8.60 (d, *J* = 5.0 Hz, 1H), 8.69 (d, *J* = 4.5 Hz, br, 1H), 12.08 (s, br, 1H).

4.3 Synthesis of Hapten2c



Scheme 3. The synthetic route of Hapten2c


Target Hapten3c was prepared based on the following scheme in 4 steps

Step 1 Synthesis of compound 2 ((E)-3-(prop-1-enyl)benzaldehyde)

A mixture of compound 1 (2.68 g, 20 mmol), ethyltriphenylphosphonium bromide (8.20 g, 22 mmol), potassium carbonate (4.20 g, 30 mmol) in dioxane (30 mL) and water (1 mL) was heated under reflux for 8 h. The reaction mixture was cooled to room temperature. Solvent was removed under vacuum. To the residue was added water (50 mL) and extracted with ethyl acetate c (50 mL \times 3). The combined organic layers were dried over sodium sulphate. Solvent removal gave a


residue. The residue was subject to silica gel column chromatography (petroleum ether: ethyl acetate = 50:1) to give a yellow oil (1.54 g, 53 %) as desired compound **2**.

Step 2 Synthesis of compound 4 ((E)-ethyl 3-(3-((E)-prop-1-enyl)phenyl)acrylate)




A mixture of compound 2 (730 mg, 5 mmol) and compound 3 (1.93 g, 5.75 mmol) in toluene was refluxed for 3 h. The mixture was cooled down and concentrated. The residue was purified with silica gel column (petroleum ether: ethyl acetate = 10 :1) to give a colorless oil as desired compound 4 (1.17 g, 100%).

Step 3 Synthesis of compound 5 (ethyl 3-(3-propylphenyl)propanoate)



To a solution of compound 4 (1.10 g, 5.44 mmol) in ethyl acetate (15 mL) was added palladium on carbon (10%, 200 mg). The reaction mixture was hydrogenated under hydrogen gas balloon for 16 h at room temperature (25 °C). The mixture was filtered to remove the palladium on carbon. The filtrate was concentrated to give desired products compound 5 as a yellow oil (1.02 g, 83%).


Step 4 Synthesis of Hapten2c




To a suspension of compound 5 (3.00 g, 13.60 mmol) in MeOH (30 mL) was added water (5 mL) and NaOH (1.97 g, 49 mmol). The mixture was then heated at 80 $^{\circ}$ C for 2 h. The mixture was


then cooled to room temperature. MeOH was removed under vacuum. To the reaction mixture was added water (20 mL). The pH value of the mixture was adjusted to 2 via addition of 1 N HCl. The mixture was extracted with ethyl acetate (50 mL × 3). The combined organic layers were dried over sodium sulphate. Solvent removal under vacuum gave a light yellow oil as desired target (2.48 g, 94%).¹H NMR (400 MHz, CDCl₃) δ 0.93 (t, *J* = 5.7 Hz, 3H), 1.58-1.67 (m, 2H), 2.55 (t, *J* = 5.7 Hz, 2H), 2.67 (t, *J* = 5.7 Hz, 2H), 2.93 (t, *J* = 6.0 Hz, 2H), 7.01-7.03 (m, 3H), 7.19-7.21 (m, 1H), 11.32 (s, br, 1H).

(A)














Figure S1. The mass spectra and ¹H NMR spectra of (A) Hapten1a, (B) Hapten2a, (C) Hapten2b, (D) Hapten2c.

5. Preparation and characterization of conjugates

The haptens with carboxylic acid groups were activated through the active-ester method and then coupled to a protein (BSA or OVA). To control the hapten-protein ratios, different combination of haptens and protein were optimized (Table S1). For Hapten1a, 12.5 μ mol, 14.6 μ mol, 16.7 μ mol, 18.7 μ mol and 20.8 μ mol of hapten1a was dissolved in 1.5 mL DMF, respectively, and NHS and DCC were added and mixed in 1.5 molar ratios. The mixture was reacted using a magnetic stirrer at room temperature for 6 h followed by the removal of the precipitates. The supernatant of mixture was dropwise added into dissolved BSA or OVA in 10 mL PBS in 1:75, 1:87.5, 1:100, 1:112.5, 1:125 ratio, respectively. In the case of other four haptens, 5.0 μ mol, 5.8 μ mol, 6.6 μ mol, 7.5 μ mol and 8.3 μ mol of haptens were used and the molar ratio of DCC and NHS was 1:1.5. The molar ratios for hapten/protein were 1:30, :35, 1:40, 1:45, 1:50 respectively. All hapten-protein conjugates were stirred for 12 h and then dialyzed in PBS for 2 days. Hapten-BSA served as an immunogen and hapten-OVA acted as coating antigens were stored at -20 °C for further use. The conjugation ratios were characterized using MALDI-TOF-MS and were calculated as follows:

Conjugation ratio =
$$\{M \text{ (conjugates)} - M \text{ (BSA)}\}/M \text{ (haptens)}$$
 (Eq.1).










Figure S2. MALDI–TOF-MS of (A) BSA, (B) Hapten1a-BSA, (C) Hapten1b-BSA, (D) Hapten2a -BSA, (E)Hapten2b-BSA, (F) Hapten2c-BSA.








Figure S3. MALDI–TOF-MS of (A) OVA, (B) Hapten1a-OVA (C) Hapten1b -OVA (D) Hapten2a-OVA, (E) Hapten2b-OVA, (F) Hapten2c-OVA.

			.•
Immunogens	ratios	Coating antigens	ratios
Hapten1a-BSA	14.6	Hapten2a-OVA	5.2
Hapten1b-BSA	14.6	Hapten2b-OVA	4.4
Hapten2a-BSA	14.4	Hapten2a-OVA	5.3
Hapten2b-BSA	13.4	Hapten2b-OVA	5.3
Hapten2c-BSA	17.0	Hapten2c-OVA	5.2

Table S2. The selected conjugates with similar hapten-to-protein molar ratios.

6. The descriptors of haptens obtained by computational chemistry

All haptens properties excluding spacer arm and trimethoprim (TMP) were built in Gaussian 09 (Gaussian, Wallingford, CT, USA). Then, the density functional theory (DFT) calculations with the M06-2X density functional and TZVP basis set were performed to optimize the haptens ^{7.8}. The fundamental vibrations were calculated by the same method to confirm whether they were true minima or not. The minimum energy conformations of haptens were shown in Figure S4. The descriptors of haptens and TMP including dipole moment (μ), the energy of the highest occupied molecular orbital (E_{HOMO}) and of the lowest unoccupied molecular orbital (E_{LUMO}), molecular energy (E) were directly extracted from output file. Energy difference between the E_{LUMO} and E_{HOMO} (Δ E_{LH}) were calculated by using Excel. Hydrophobic constant (LogP), cLogP and molecular weight (MW)were extracted by using ChemBio3D (PerkinElmer). Molecules volume (V_m), surface area (SA), polar surface area (PSA) and molecular polarity index (MPI) were extracted by using Multiwfn⁹. Solvent accessible surface areas (SASA) were extracted by using VMD¹⁰.




Figure S4. The minimum energy conformations of haptens which excluding the spacer arm. The elements are represented in the following manner: oxygen, red; nitrogen, blue; hydrogen, white; and carbon, off white.

Haptens ^a	Hapten1a	Hapten1b	Hapten2a	Hapten2b	Hapten2c	TMP
descriptors	NH ₂ N H ₂ N N	OCH ₃ OCH ₃	NH-CH ₃	O O CH ₃		$H_2N \xrightarrow{N} N \xrightarrow{OCH_3} OCH_3$
μ	2.2508	1.803	3.818	2.5515	0.4963	4.0933
MPI	15.22	11.08	13.66	11.02	6.90	12.82
cLogP	-0.336	1.4421	0.108	0.767	3.699	0.9811
LogP	-0.28	1.65	-0.16	0.52	3.36	1.43
MW	110.12	168.19	136.15	137.14	120.2	290.32
E _{HOMO}	-0.26825	-0.25055	-0.32723	-0.33154	-0.29427	-0.26393
E _{LUMO}	0.024254	0.039589	-0.0302	-0.03798	0.024412	0.017181
ΔE_{LH}	0.292507	0.290136	0.297032	0.293568	0.31868	0.281107
Е	-375.043	-575.756	-456.257	-476.128	-350.136	-988.928
$\mathbf{V}_{\mathbf{m}}$	136.7412	214.8453	172.7826	167.8135	184.8898	353.1313
SA	145.2302	211.5105	176.7082	173.2873	185.6047	321.5312
PSA	95.21	107.46	94.94	89.86	41.14	190.87
SASA	273.0459	369.1366	313.8543	309.5389	319.3560	497.0549

Table S3. Molecular	descriptors	of main	structure	of all	haptens

^a Here, the structures used for calculation chemistry is the subtractive haptens which excluding the spacer arm.

7. Immunization procedure of mice

Ten female BALB/c mice for each hapten conjugates, 6–8 weeks old, were immunized subcutaneously with each 100 μ g of immunogens in 0.25 mL of 0.9% NaCl and 0.25 mL of Freund incomplete adjuvant. On the 25th and 50th days after the initial injection, mice were boosted with 100 μ g of immunogen in Freund complete adjuvant. One week after injection, antisera samples obtained from the eye socket of mice were collected to detect the sensitivity and specificity based on the ELISA.

Immunogens	Dose/mouse	Number of immunizations	Interval time (d)	Number of mice
Hapten1a-BSA	100 µg	3	25	10
Hapten1b-BSA	100 µg	3	25	10
Hapten2a-BSA	100 µg	3	25	10
Hapten2b-BSA	100 µg	3	25	10
Hapten2c-BSA	100 µg	3	25	10

Table S4. The information of immunization procedures

8. The determination of titers and affinity

8.1 The determination of titers

The titers of antibody were determinated by noncompetitive ELISA and the dilution of antibody when furnishing OD_{max} between 1.5 and 2.0 as the following procedure: polystyrene 96-well microtiter plates were coated with each homogenous coating antigen (100 µL/well) incubated at 4 °C overnight. The plates were washed three times with washing buffer, and then blocked with blocking buffer (300 µL/well) at 37 °C for 1 h. Antibody (100 µL/well) were added to wells. Unbound compounds were removed by washing solution after incubation for 30 min at 37 °C. Goat anti-mouse IgG-HRP (1/5000 in PBS, 100 µL/well) were added and incubated at 37 °C for 30 min and then washed three times with washing buffer. The substrate solution (100 µL/well) was added and incubated at 37 °C for 15 min before adding 2 M H₂SO₄(50 µL/well).

Absorbance values were measured at 450 nm.

8.2 The determination of affinity

The affinity of antibodies was determinated by using competitive indirect ELISA (ciELISA) and expressed by inhibition ratio values as followed. The microplates were firstly coated with 1µg of each homogenous coating antigen (100 µL/well) which was diluted with CB buffer and then incubated at 4 °C overnight. The coating solution in the ELISA plates was then discarded. Blocking buffer was then added to the plates (150 µL/well) which were placed in an incubator for 1 h at 37 °C. The corresponding haptens (50 µL) at 10 µg/L were added to the wells as well as 50 µL of antibody at titer dilution. After an incubation of 30 min at 37 °C, the plates were washed by PBST for two times. Goat anti-mouse IgG (HRP labeled) (1:5000, 100 µL/well) was then added and incubated for 30 min at incubator. Then 100 µL TMB substrate was added into wells and incubated for 15 min at 37 °C after washing. Then 2 mol $L^{-1} H_2SO_4$ (50 µL/well) was used to stop the enzymatic reaction and the OD values of 450 nm was measured.

The inhibition ratio was calculated by using the following equation:

Inhibition ratio =
$$(B_0 - B)/B_0$$
 (Eq. 2)

where B_0 and B are the responses the OD values in the absent of haptens and in the concentration of haptens at 10 mg/L.

Hontons	Hapten Structures	MDI	1 st immunization		2 nd immunization		3 rd immunization	
Haptens		MPI -	Titers ^a	Inhibition ratios ^b	Titers	Inhibition ratios	Titers	Inhibition ratios
Hapten1a	NH ₂ N H ₂ N N COOH	15.22	1233	1.09	3000	0.99	3360	0.92
Hapten1b	HOOC OCH ₃ OCH ₃	11.08	12666	61.02	28880	65.98	38400	77.52
Hapten2a	NH-CH ₃	13.66	130	9.43	333	18.23	700	44.19
Hapten2b	O COOH	11.02	380	5.01	600	14.13	1100	31.09
Hapten2c	Соон	6.90	2488	45.42	5600	73.24	7111	90.01

Table S5. The detailed information of antibodies titers and inhibition ratios from three immunizations

^aThe titers of antibody were determinated by noncompetitive ELISA and the dilution of antibody when furnishing ODmax between 1.5 and 2.0. Data were average values of 10 mice and each mouse obtained in triplicate.

^bThe inhibition ratio was calculated by using the following equation: Inhibition ratio = $(B_0-B)/B_0$, where B_0 and B are the responses the OD values in the absent of haptens and in the concentration of haptens at 10 mg/L. Data were average values of 10 mice and each mouse obtained in triplicate.

References

- 1 Martlbauer E, Meier R, Usleber E, Terplan G. Food Agric Immunol, 1992, 4: 219-228.
- 2 Rtlbauer EM, Usleber E, Schneider E, Dietrich R. Analyst, 1994, 119: 2543–2548.
- 3 Chen Y, Liu L; Song S, Kuang H, Xu C. Food Agric Immunol, 2016, 27: 830-840.
- 4 Chen Y, Liu L, Xie Z, Zhu J, Song S, Kuang H. Food Agric Immunol, 2017, 28: 1046-1057.

5 Han X, Sheng F, Kong D, Wang Y, Pan Y, Chen M, Tao Y, Liu Z, Ahmed S, Yuan Z, Peng D. *Food Chem*, 2019, 280: 20-26.

6 Li H, Ma S, Zhang X, Li C, Dong B, Mujtaba MG, Wei Y, Liang X, Yu X, Wen K, Yu W,

Shen J, Wang Z. J Agric Food Chem, 2018, 66: 11170–11179.

- 7 Weigend F, Ahlrichs R. Phys Chem Chem Phys, 2005, 7: 3297-305.
- 8 Zhao Y, Truhlar DG. *Theor Chem Acc*, 2008, 120: 215-241.
- 9 Lu T, Chen F. J Comput Chem, 2012, 33: 580-592.
- 10 Humphrey W, Dalke A, Schulten K. J Mol Graph, 1996, 14.